. 2017 May 18;8(6):1573–1586. doi: 10.1016/j.stemcr.2017.04.019

Table 1.

Biological and Cytogenetic-Molecular Characteristics of Blasts and BM-MSCs from Diagnostic AML Patients

Patient ID	Diagnostic	Cytogenetics	Molecular	Age (years)	Gender	Blasts (%)	Risk	Cytogenetic/Molecular Alteration in BM-MSCs
AML01	AML-M4	46, XY, inv(16)	Cbfb-MYH11	20	M	56	low	negative
AML02	AML-M5	46, XY, inv(16)	Cbfb-MYH11	1	M	50	low	negative
AML03	AML-M2	46, XY, t(8;21)	AML1-ETO	30	M	39	low	ND
AML04	AML	46, XX	NPM1^MUT, IDH1^MUT	20	F	92	low	negative
AML05	AML	46, XY	NPM1^MUT	18	M	32	low	negative
AML06	AML	46, XY, t(5;15)	cEBPa^MUT	66	M	15	low	negative
AML07	AML-M4	46, XX	NPM1^MUT	37	F	80	low	negative
AML08	AML-M3	46, XX t(15;17)	PML-RARa	59	F	90	low	negative
AML09	AML-5b	46, XX	NPM1^MUT	70	F	34	low	ND
AML10	AML-M3	46, XY, t(15;17)	PML-RARa	27	M	92	low	negative
AML11	AML	46, XY	NPM1^MUT	81	M	45	low	ND
AML12	AML	46, XY	NPM1^MUT	80	M	49	low	negative
AML13	AML	46, XX	NPM1^MUT	71	F	45	low	ND
AML14	AML	46, XX	NPM1^MUT	78	F	67	low	negative
AML15	AML-M3	46, XY, t(15;17)	PML-RARa	25	M	90	low	negative
AML16	AML-M3	46, XY, inv(16)	Cbfb-MYH11	27	M	40	low	negative
AML17	AML	46, XY	–	10	M	92	int	ND
AML18	AML	46, XY	–	81	M	35	int	ND
AML19	AML	46, XY	–	77	M	45	int	ND
AML20	AML	46, XX	–	61	F	71	int	ND
AML21	AML-M4	46, XY	–	86	M	50	int	ND
AML22	AML	46, XX	–	52	F	79	int	ND
AML23	AML	46, XY	–	78	M	60	int	ND
AML24	AML-M4	46, XX	–	44	F	65	int	ND
AML25	AML	46, XY	–	61	M	1	int	ND
AML26	AML-M7	46, XY	–	60	M	60	int	ND
AML27	AML	46, XY	–	56	M	40	int	ND
AML28	AML-M5	46, XX, t(11;19)	MLL-ENL	48	F	77	high	negative
AML29	AML	45, XY, −7	–	80	M	85	high	negative
AML30	AML-M2	46, XX, t(8;21)	AML1-ETO, FLT3-ITD	4	F	40	high	negative/negative
AML31	AML-M4	46, XX, t(9;11)	MLL-AF9	63	F	90	high	negative
AML32	AML	45, XY, −7	–	73	M	15	high	negative
AML33	AML-M5	46, XY	NPM1^MUT, FLT3^del	77	M	80	high	negative/negative
AML34	AML-M5	46, XX	NPM1^MUT, FLT3-ITD	65	F	90	high	negative/negative
AML35	AML-M1	46, XX	NPM1^MUT, FLT3-ITD	73	F	90	high	negative
AML36	AML	46, XX, 11q23	MLL-MLL (PTD)	74	F	70	high	ND
AML37	AML-M1	46, XX, t(9;11)	MLL-AF9	77	F	80	high	negative
AML38	AML	45, XY, −7	–	69	M	22	high	negative
AML39	AML-M4	46, XY	NPM1^MUT, FLT3^MUT, WT1^MUT	42	M	99	high	negative
AML40	AML	CK	–	35	M	80	high	negative
AML41	AML	47, XY (+mar)	FLT3 D835^MUT	81	M	47	high	negative
AML42	AML-M2	46, XX	MLL-PTD⁺	76	F	40	high	negative
AML43	AML	46, XY, −7q	–	53	M	56	high	negative
AML44	AML-M4	47, XY, +8	WT1⁺, TP53 exon 6⁺	69	M	35	high	ND
AML45	AML-M4	46, XX	MLL-PTD⁺	68	F	65	high	negative
AML46	AML	46, XX	FLT3-ITD	8	F	95	high	negative
HD01	normal	46, XX	–	37	F	0	HD	ND
HD02	normal	46, XY	–	34	M	0	HD	ND
HD03	normal	46, XY	–	41	M	0	HD	ND
HD04	normal	46, XY	–	42	M	0	HD	ND
HD05	normal	46, XY	–	42	M	0	HD	ND
HD06	normal	46, XX	–	34	F	0	HD	ND
HD07	normal	46, XY	–	28	M	0	HD	ND
HD08	normal	46, XX	–	49	F	0	HD	ND
HD09	normal	46, XY	–	56	M	0	HD	ND
HD10	normal	46, XX	–	34	F	0	HD	ND

HD, healthy donor; CK, complex karyotype; int, intermediate risk; M, male; F, female; –, no mutations found for FLT3, NPM1, cEBPa, WT, and IDH1; ND, not determined.